Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Gastric cancer is a high incidence in Asia, and one of the leading cause of death in Korea. A
cure rate is improving due to early diagnosis. However, the 5-year survival rate of gastric
cancer excluding early gastric cancer is about 40 ~ 67%. Therefore, several methods for
lowering the recurrence rate have been attempted and concurrent chemoradiotherapy can be
considered as a method to lower the recurrence rate of gastric cancer. The purpose of this
study is to evaluate the pathologic response rate and safety of patients who underwent
surgery after chemoradiotherapy.